Inicio › Leucemia linfocítica crónica › Wisconsin
Ensayos clínicos de Leucemia linfocítica crónica en Wisconsin
19 estudios sobre Leucemia linfocítica crónica buscan participantes en Wisconsin.
Ciudades en Wisconsin
Texto oficial del estudio (inglés)
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Aspirus Cancer Care-Antigo-Volm Cancer Center, Antigo
- Duluth Clinic Ashland, Ashland
- Marshfield Medical Center-EC Cancer Center, Eau Claire
- y 14 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT04269902Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Aspirus Cancer Care-Antigo-Volm Cancer Center, Antigo
- ThedaCare Regional Cancer Center, Appleton
- ThedaCare Regional Medical Center - Appleton, Appleton
- y 50 más
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 40 a 75 · Todos los sexos · Actualizado el 4 nov 2026 · NCT05334069Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Duluth Clinic Ashland, Ashland
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay
- y 7 más
ReclutandoFase 3
Edades de 65 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07321652A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- The Medical College of Wisconsin, Milwaukee
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07221500Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Medical College of Wisconsin, Milwaukee
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 oct 2026 · NCT07648264A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- SSM Health Dean Medical Group - South Madison Campus Health Research/Circuit Clinical ( Site 0048), Madison
- University Hospital and UW Health Clinics ( Site 0006), Madison
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 oct 2026 · NCT06136559A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Medical College of Wisconsin, Milwaukee
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07277231A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Gunderson Health System, La Crosse
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT06973187Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Medical College of Wisconsin, Milwaukee
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT03666000A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Medical College of Wisconsin, Milwaukee
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 jul 2026 · NCT05131022Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
- Medical College of Wisconsin, Milwaukee
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 mar 2026 · NCT07218510A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Medical College of Wisconsin, Milwaukee
ReclutandoFase 4
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 mar 2026 · NCT06876649A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Medical College of Wisconsin, Milwaukee
ReclutandoFase 4
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 mar 2026 · NCT06876662CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
- Medical College of Wisconsin and Froedtert Hospital, Milwaukee
ReclutandoFase 1/2
Edades de 18 a 80 · Todos los sexos · Actualizado el 23 feb 2026 · NCT04186520Study of SGR-1505 in Mature B-Cell Neoplasms
- Medical College of Wisconsin, Milwaukee
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 feb 2026 · NCT05544019AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- The Medical College of Wisconsin, Milwaukee
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 dic 2025 · NCT05602363In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
- University of Wisconsin, Madison
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 nov 2025 · NCT04785989Long-term Follow-up Study of Patients Receiving CAR-T Cells
- Froedtert Hospital & Medical College of Wisconsin, Milwaukee
ReclutandoEstudio observacional
Edades de 18 a 80 · Todos los sexos · Actualizado el 10 nov 2025 · NCT03375619A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
- Center for International Blood and Marrow Transplant Research (CIBMTR), Milwaukee
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 feb 2025 · NCT06788639De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.